HSBC Holdings
BMRN icon

HSBC Holdings’s BioMarin Pharmaceuticals BMRN Stock Holding History

HSBC Holdings’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-2,000
Closed -$247K – 2725
2020
Q2 		$247K Buy
+2,000
New +$199K ﹤0.01% 2231

Other funds holding BMRN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

HSBC Holdings's BMRN Position: Q1 2026 in Review

HSBC Holdings reduced its BioMarin Pharmaceuticals (BMRN) stake by 70% in Q1 2026, selling an estimated $20.6M and leaving 148,182 shares worth $8.36M. The position accounts for ﹤0.01% of the portfolio, ranked #982.

HSBC Holdings first reported a position in BMRN in Q2 2013 and has held it in 52 quarters since. The position peaked at $53.9M in Q3 2023. 555 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.

  • HSBC Holdings held 148,182 shares of BioMarin Pharmaceuticals worth $8.36M as of Q1 2026.
  • HSBC Holdings sold 352,814 BioMarin Pharmaceuticals shares in Q1 2026, an estimated $20.6M.
  • BioMarin Pharmaceuticals made up ﹤0.01% of HSBC Holdings's portfolio in Q1 2026, its #982 holding.
  • HSBC Holdings first reported a position in BioMarin Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
  • HSBC Holdings's BioMarin Pharmaceuticals position peaked at $53.9M in Q3 2023.
  • 555 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.

Based on HSBC Holdings's 13F filing for Q1 2026, filed 30 Apr 2026.